Elena Tóthová

1.1k total citations
21 papers, 631 citations indexed

About

Elena Tóthová is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Elena Tóthová has authored 21 papers receiving a total of 631 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 10 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Elena Tóthová's work include Multiple Myeloma Research and Treatments (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Elena Tóthová is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Elena Tóthová collaborates with scholars based in Czechia, Slovakia and Austria. Elena Tóthová's co-authors include Heinz Gisslinger, Roman Hájek, Heinz Ludwig, Richard Greil, Niklas Zojer, Miklós Egyed, Boris Labar, Johannes Drach, Axel Hinke and Ingrid Kühn and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Journal Of Haematology.

In The Last Decade

Elena Tóthová

18 papers receiving 614 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Elena Tóthová 556 309 256 220 161 21 631
D. W. Kim 507 0.9× 67 0.2× 411 1.6× 124 0.6× 261 1.6× 9 592
Mindaugas Jurgutis 281 0.5× 203 0.7× 373 1.5× 62 0.3× 137 0.9× 7 447
Amity Frede 396 0.7× 58 0.2× 323 1.3× 123 0.6× 174 1.1× 13 472
Elena Mishchenko 291 0.5× 220 0.7× 384 1.5× 58 0.3× 159 1.0× 12 461
Giovanna Rege Cambrin 518 0.9× 110 0.4× 405 1.6× 58 0.3× 191 1.2× 28 609
Lucı́a Villalón 224 0.4× 63 0.2× 142 0.6× 107 0.5× 61 0.4× 25 400
Giambattista Bertani 302 0.5× 188 0.6× 103 0.4× 70 0.3× 29 0.2× 20 460
C. Matsouka 322 0.6× 267 0.9× 83 0.3× 149 0.7× 15 0.1× 9 383
D.-W. Kim 527 0.9× 44 0.1× 406 1.6× 106 0.5× 252 1.6× 5 590

Countries citing papers authored by Elena Tóthová

Since Specialization
Citations

This map shows the geographic impact of Elena Tóthová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Tóthová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Tóthová more than expected).

Fields of papers citing papers by Elena Tóthová

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elena Tóthová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Tóthová. The network helps show where Elena Tóthová may publish in the future.

Co-authorship network of co-authors of Elena Tóthová

This figure shows the co-authorship network connecting the top 25 collaborators of Elena Tóthová. A scholar is included among the top collaborators of Elena Tóthová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Tóthová. Elena Tóthová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Novotná, Gabriela Balíková, et al.. (2015). Incidence and Prognostic Value of Known Genetic Aberrations in Patients with Acute Myeloid Leukemia – a Two Year Study. Klinicka onkologie. 28(4). 278–283. 2 indexed citations
2.
Faber, Edgar, Jan Mužı́k, Eva Janoušová, et al.. (2015). Significance of anemia in patients with CML at diagnosis andduring the treatment with imatinib outside the clinical trials:CAMELIA registry experience. 1 indexed citations
3.
Ráčil, Zdeněk, Martina Tošková, Iva Kocmanová, et al.. (2012). Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics. Leukemia & lymphoma. 54(5). 1042–1047. 5 indexed citations
4.
Voglová, J, Edgar Faber, Hana Klamová, et al.. (2011). Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia. Neoplasma. 58(3). 256–262. 18 indexed citations
5.
6.
Ludwig, Heinz, Zdeněk Adam, Roman Hájek, et al.. (2010). Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study. Journal of Clinical Oncology. 28(30). 4635–4641. 102 indexed citations
7.
Ludwig, Heinz, Zdeněk Adam, Elena Tóthová, et al.. (2009). A147 Thalidomide/Interferon Versus Interferon Maintenance After Thal/Dex Versus MP. Clinical Lymphoma & Myeloma. 9. S24–S25.
8.
9.
Ludwig, Heinz, Zdeněk Adam, Richard Greil, et al.. (2009). Reversal of acute renal impairment bybortezomib-doxorubicin-dexamathasone in multiple myeloma.Results from an phase II study. 1 indexed citations
10.
11.
12.
Ludwig, Heinz, Roman Hájek, Elena Tóthová, et al.. (2008). Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood. 113(15). 3435–3442. 148 indexed citations
13.
Tóthová, Elena. (2007). MOŽNOSTI LIEČBY MNOHOPOČETNÉHO MYELÓMU. 1(1). 14–17.
14.
Ludwig, Heinz, Johannes Drach, Elena Tóthová, et al.. (2005). Thalidomide-Dexamethasone Versus Melphalan-Prednisolone as First Line Treatment in Elderly Patients with Multiple Myeloma: An Interim Analysis.. Blood. 106(11). 782–782. 20 indexed citations
15.
Ludwig, Heinz, Johannes Drach, Elena Tóthová, et al.. (2005). Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: An interim analysis. Journal of Clinical Oncology. 23(16_suppl). 6537–6537. 8 indexed citations
16.
Tóthová, Elena, et al.. (2003). Efficiency of in vivo purging with autologous stem cell transplantation and monoclonal antibody in B-cell lymphomas.. PubMed. 50(1). 22–5. 7 indexed citations
17.
Tóthová, Elena. (2002). [New views on the treatment of chronic myelocytic leukemia. Literature review].. PubMed. 48(3). 230–3. 1 indexed citations
18.
Tóthová, Elena, et al.. (2002). High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy.. PubMed. 49(3). 141–4. 52 indexed citations
19.
Tóthová, Elena, et al.. (2001). P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome.. PubMed. 48(5). 393–7. 8 indexed citations
20.
Neuwírtová, R, Jaroslav Jelı́nek, Jana Musilová, et al.. (1997). [Mixed myelodysplastic and myeloproliferative syndromes].. PubMed. 136(23). 724–9. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. W. Kim Breakdown of academic impact, for papers by Mindaugas Jurgutis Breakdown of academic impact, for papers by Amity Frede Breakdown of academic impact, for papers by Elena Mishchenko Breakdown of academic impact, for papers by Giovanna Rege Cambrin Breakdown of academic impact, for papers by Lucı́a Villalón Breakdown of academic impact, for papers by Giambattista Bertani Breakdown of academic impact, for papers by C. Matsouka Breakdown of academic impact, for papers by D.-W. Kim
Rankless by CCL
2026